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chronically T. cruzi infected Syrian hamster, shown by our group to develop a cardiomy-
opathy resembling human CCC.
Methods: female Syrian hamsters were injected intraperitoneally with 105 Y strain T. cruzi
parasites (40) or saline solution (20, N group). At 9 months post-infection (PI), surviving
infected animals were divided in 2 groups: (T) treated with 2.5mg of Etanercept/Kg body
weight s.c. 2x/week for 9 weeks and (I) no further treatment. Animals were subjected to
2-D, pulsed-wave color Doppler and M mode echocardiography, under tribromoethanol
anesthesia, at three time points: before T. cruzi infection, at 8 ½ and 11 months PI. At 11
months PI, animals were euthanized, and heart/body weight index (HW/BW) was calcu-
lated.
Results: median baseline echocardiographic measurements were similar between all
treatment groups. Deaths between 9 and 11 months PI were more frequent in the T (8/
13) than in I group (4/10). At 11 months PI, fractional shortening (FS) was significantly
diminished in the T (22.0 [9.5-47.7]) as compared to the I group (36.6 [25.7-43.9]
(median [min-max]). Left ventricle diastolic diameter (LVDD) and HW/BW index were sig-
nificantly increased at 11 months PI in the T group (0.63 [0.41-0.73]; 6.1 [4.0-8.7],
respectively) as compared to I group (0.57 [0.46-0.67]; 4.1 [4.3-5.9], respectively). In the
T group, FS and LVDD were significantly different between 8 ½ and 11 months PI, but
remained similar in I or N groups.
Conclusions: TNF blockade worsens left ventricular dysfunction in chronically T. cruzi
infected hamsters. Therefore, Etanercept should not be considered for the treatment of
CCC patients.
3:00 p.m.
849-5 Alterations in Cell Signaling Pathways During 
Pregnancy and Postpartum Cardiac Remodeling
Ana M. Duque Gonzalez, Juan C. Osorio, Seema Mital, Columbia University, New York, 
NY
Background: The cardiac molecular changes induced by load during pregnancy are not
well understood. We investigated the role of mitogen-activated protein kinases (MAPK),
protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) in post-partum (PP)
cardiac remodeling.
Methods: Adult female Sprague-Dawley rats were divided into non-pregnant (n=5), 16
days (d) pregnant (n=4), PP d0 (n=7), PP d8 (n=6), and PP d14 (n=10). Rats underwent
serial 2-D echocardiography to measure cardiac size and function. Protein expression in
ventricular myocardium was measured by Western blot for MAPKs (p38, p44/42, JNK),
protein kinase B (Akt) and eNOS. Blot density was expressed in arbitrary units (AU).
Results: Echocardiography: During pregnancy, there was an increase in LV ejection frac-
tion (EF) (63.7±3% to 73.7±1.6%, p<0.05) and LV mass (0.62±0.03 to 1.1±0.04 g,
p<0.01), and decrease in LV systolic area (LVSA) (0.3±0.01 to 0.23±0.02 cm2, p<0.05).
In the immediate PP period, LV function decreased by 23% (EF= 56.5±2.9%, p<0.01), LV
diastolic area increased by 13%, and LVSA by 56%. By PP d14, LV mass decreased,
however, LV dilatation and dysfunction persisted. Protein expression: MAPK expression
did not change during pregnancy. However, p44/42 increased (29±1 to 37±1 AU) and p38
MAPK decreased (35±2 to 22±2 AU) by PP d14 (p<0.01). Akt and eNOS peaked at PP
d14 (p<0.01). LV mass showed a positive correlation with p38 MAPK (r=0.7) and an
inverse correlation with p44/42 (r=0.72). LVDA inversely correlated with JNK expression
(r=0.76).
Conclusion: The PP period is characterized by LV wall thinning, dilatation and dysfunc-
tion possibly related to an increase in myocardial p44/42 and decrease in p38 MAPK
expression, mediators of cardiac hypertrophic responses. The concomitant increase in
Akt and eNOS also suggests a role for Akt-dependent pathways. Understanding the sig-
naling pathways of physiologic cardiac remodeling can be used to better characterize
pathological processes like PP cardiomyopathy.
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849-6 Apoptotic Cleavage of Contractile Proteins in End-Stage 
Heart Failure
Lorenz Bott-Fluegel, Hans-Joerg Weig, Karl-Ludwig Laugwitz, Michael Naebauer, Diana 
Grewe, Melchior Seyfarth, Medizinische Klinik and Deutsches Herzzentrum, Technische 
Universitaet, Munich, Germany, Medzinische Klinik und Poliklinik, Klinikum Grosshadern, 
LMU Muenchen, Munich, Germany
Background: There is strong evidence that apoptosis plays an important part in the
pathogenesis of heart failure. In a previous study we showed that activated caspase-3
cleaves the essential myosin light chain-1 (MLC-1) in tachycardia-induced heart failure in
rabbits. However, it is unclear to what extent this apoptotic program is executed in human
heart failure. Therefore, we examined human myocardial samples for the cleavage of
contractile proteins. Methods: Myocardial specimens from 6 patients with either ischemic
cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) wererapidly collected after
explantation and stored at -80 °C. The samples were then minced and lysed, and cytoso-
lic and nuclear fractions were prepared. After electrophoresis and blotting, samples were
probed with the respective antibody. Low-abundancy proteins including MLC-1 and
caspase-3 were enriched by immunoprecipitation with the specific antibody, and then
electrophoresed as above.
Results: Caspsase-3 activation was demonstrated in 60% of DCM and 55% of ICM
hearts. Cleavage of common targets of caspase-3, such as poly-(ADP-ribose)-poly-
merase (PARP), a DNA repair enzyme, or gelsolin was shown in 75% of DCM and 80%
of ICM hearts. Furthermore, we showed that MLC-1 was cleaved in myocardial speci-
mens of DCM (90%) and ICM (75%) patients. Other structural or contractile proteins like
myosin heavy chain (MHC), alpha sarcomeric actin, troponins, tropomyosin, and alphaB
crystallin were not cleaved. Fragmentation of DNA could be observed only in a fraction of
hearts, 15% in the DCM and 20% in the ICM group.
Conclusion: In this study we demonstrated that caspase-3, a key apoptosis protein, is
activated in human heart failure. We observed cleavage of PARP, a nuclear DNA repair
protein and typical target of caspases. Cleavage of the contractile protein MLC-1 was
found in 75-90% of human heart failure specimens, suggesting that apoptotic cleavage of
contractile proteins also occurs in human heart failure and may partially explain the dete-
rioration of ventricular function. Other contractile proteins were not cleaved.
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1163-109 Ongoing Myocardial Damage in Severe Heart Failure: 
Prognostic Usefulness of Cardiac Troponin T 
Monitoring to Identifying High-Risk Patients
Eduardo R. Perna, Stella M. Macin, Juan P. Cimbaro Canella, Natalia Augier, Ariel E. 
Pitzus, Jorge L. Riera Stival, Jorge Cialzeta, Edgar Garcia, Alejandro Barbagelata, Eloisa 
Jantus, Instituto de Cardiologia J. F. Cabral, Corrientes, Argentina, Hospital Italiano, 
Buenos Aires, Argentina
Background: The progression of heart failure (HF) is related to myocyte loss due to sev-
eral abnormalities, and it can be detected by cardiac troponin T (cTnT). We assessed the
hypothesis that cell loss overtime in stable HF could identifiy a subgroup with worse prog-
nosis.
Methods: Clinical, echocardiographic and 6 minute walk test data were prospectively
obtained baseline and after one year in 115 outpatients with HF and LVEF less than 40%.
Baseline, 3, 6 and 12 months blood samples were assayed for cTnT (3rd generation) and
levels >=0.02 ng/mL were considered abnormal. Patients were classified as Group 1: all
cTnT samples (-), Group 2: one cTnT (+), and Group 3 two or more cTnT (+).
Results: Mean age was 61±11 years, 75% were male and 62% had coronary heart dis-
ease. Population was classified in Group 1=62(54%), 2=28(24%), and 3=25(22%). Com-
parison is detailed in Table. Eighteen-month free HF-hospitalization survival in Groups 1,
2 and 3 was 63, 46 and 17% (p=0.0001), and in a Cox-proportional hazard model, the
variables independently associated with events were the following: compensated HF at
admission (HR=0.42,95%CI=0.20-0.89,p=0.029), NYHA class III-IV
(HR=2.0,95%CI=1.13-3.7,p=0.019) and number of positive samples for cTnT
(HR=1.9,95%CI=1.4-2.6,p<0.0001).
Conclusion: cTnT elevation in severe HF correlated with disease severity and functional
deterioration. Moreover, myocardial damage was a strong predictor of worsening HF,
suggesting a role of cTnT-based monitoring to detect high risk patients
1163-110 Clinical and Prognostic Role of IgG3 Autoantibodies in 
Patients With Heart Failure: A Substudy of the 
Vasogen's Immunmodalatory Therapy
Rahat S. Warraich, James B. Young, Francois Sestier, Katy Becker, Susan McRee, 
Magdi H. Yacoub, Guillermo Torre-Amione, Harefield Hospital, NHLI of Imperial College, 
Middlesex, United Kingdom
Clinical benefits of Vasogen's Immune Modulation Therapy (IMT) have been reported in a
No. of inflammatory conditions. Results from a recent multi-center, double-blind, placebo-
controlled study using this novel non-pharmacological, anti-inflammatory treatment regi-
men in patients (pts) with chronic heart failure (HF) demonstrated a reduction in the risk
of all-cause mortality and hospitalization (hosp) in the treatment vs placebo group. How-
ever, the potential targets for this treatment in HF are not known. We have previously
identified an immunoglobulin (Ig) subclass G3 response in pts with HF. Given the poten-
tial capacity of G3-Igs to mediate tissue injury, the study sought to investigate the clinical
relevance of class/subclass-Igs and cytokines in the IMT-study cohort.
Levels of Igs, total (Gt) and subclasses; G1, G2 and G3 against human cardiac myosin,
TNF-α , INF-γ , IL-6 and IL-10 were evaluated (blindly) in 71 study pts (mean LVEF 22%,
NYHA class III/IV). Pts in both groups (IMT; n=36, placebo; n=35) were matched for age,
gender, functional class (fc), exercise tolerance and drug therapy. Baseline levels of Ig-
Gt, 1, 2, and the cytokines were similar in both groups, whereas G3-response was non-
significantly lower in the IMT group vs placebo; 0.19 (0.09-0.40) and 0.37 (0.1-0.54),
Table (* p<0.02 vs baseline)
Group 1 Group 2 Group 3 p value
NYHA Class, mean (SD) Baseline 2.3(0.8) 2.5(0.7) 2.5(0.8) 0.25
12 months 2.4(0.8) 2.7(0.7) 3.3(0.6)* <0.0001
EF, % (SD) Baseline 28.5(8) 22.3(8) 25.4(8) 0.003
12 months 36(11)* 32.7(12)* 30.1(11) 0.17
Mortality, % 12 months 8.1 28.6 12 0.032
Emergency visit for worsening 
HF, % 
12 months 22.6 60.7 88 <0.0001
